Immunotherapy has completely changed the treatment of solid tumors. Although immune checkpoint inhibitors (ICIs) seem to be an appealing alternative to chemotherapy, especially in elderly patients, due to a more tolerable toxicity profile, they can lead to a peculiar variety of immune-related adverse events (irAEs). However, data on tolerability and outcome of ICIs in the elderly are lacking due to poor accrual in clinical trials of these patients.
Safety of Immune Checkpoint Inhibitors in Elderly Patients: An Observational Study / Paderi, Agnese; Fancelli, Sara; Caliman, Enrico; Pillozzi, Serena; Gambale, Elisabetta; Mela, Marinella Micol; Doni, Laura; Mazzoni, Francesca; Antonuzzo, Lorenzo. - In: CURRENT ONCOLOGY. - ISSN 1718-7729. - STAMPA. - 28:(2021), pp. 3259-3267. [10.3390/curroncol28050283]
Safety of Immune Checkpoint Inhibitors in Elderly Patients: An Observational Study
Paderi, Agnese;Fancelli, Sara;Caliman, Enrico;Pillozzi, Serena;Gambale, Elisabetta;Antonuzzo, Lorenzo
2021
Abstract
Immunotherapy has completely changed the treatment of solid tumors. Although immune checkpoint inhibitors (ICIs) seem to be an appealing alternative to chemotherapy, especially in elderly patients, due to a more tolerable toxicity profile, they can lead to a peculiar variety of immune-related adverse events (irAEs). However, data on tolerability and outcome of ICIs in the elderly are lacking due to poor accrual in clinical trials of these patients.
| File | Dimensione | Formato | |
|---|---|---|---|
|
curroncol-28-00283 (1).pdf
accesso aperto
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Creative commons
Dimensione
430.59 kB
Formato
Adobe PDF
|
430.59 kB | Adobe PDF |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
